» Articles » PMID: 25755616

Treatment Algorithms for Managing Hepatocellular Carcinoma

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2015 Mar 11
PMID 25755616
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Early diagnosis and aggressive therapy improves outcome in hepatocellular carcinoma (HCC). Several potentially curative as well as palliative treatment options are available for patients. The choice of therapy is influenced by factors such as extent of tumor and severity of underlying liver dysfunction as well as availability of resources and of expertise. A systematic, algorithmic approach would ensure optimal therapy for each patient and is likely to improve outcomes. Even after receiving therapy for HCC, patients remain at risk for recurrent HCC as well as progression of underlying cirrhosis. Proper assessment and monitoring is needed for the underlying liver disease, which may progress to liver failure and have a major impact on long-term survival. Comprehensive care for patients with cirrhosis includes interventions such as antiviral therapy for HBV and HCV, abstention from alcohol, management of fatty liver disease, endoscopic surveillance and treatment for complications of portal hypertension and, if indicated, immunization against HAV and HBV. An algorithmic approach is useful for choosing the most appropriate treatment option for the individual patient from among the various options that are available. The general consensus is that the BCLC system should be preferred for staging HCC as it is useful in predicting outcomes and planning treatment. The BCLC system classifies patients with HCC into five categories: very early, early, intermediate, advanced, and terminal. It incorporates data on tumor status (number and size of nodules, vascular invasion, extra-hepatic spread), liver function (CTP status, presence of portal hypertension) and overall health status (constitutional symptoms, cancer symptoms, performance status). Treatment allocation according to sub-class of patients is a merit of the BCLC system; a few limitations have been noted, particularly with respect to patients with BCLC stage B and C disease. The treatment algorithm as per BCLC system is summarized in this review.

Citing Articles

An In-depth Review on in the Management of Liver Health and Liver Cancer.

Saraswat I, Goel A, Gupta J Anticancer Agents Med Chem. 2024; 25(1):24-34.

PMID: 39225208 DOI: 10.2174/0118715206307964240821051756.


An observational study on tumour response of portal vein tumour thrombus in hepatocellular carcinoma.

Mehra P, Kataria T, Gupta D, Krishan S J Radiosurg SBRT. 2023; 8(4):257-264.

PMID: 37416331 PMC: 10322169.


First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review.

Zhang L, Sun J, Wang K, Zhao H, Zhang X, Ren Z Curr Oncol. 2022; 29(10):7305-7326.

PMID: 36290852 PMC: 9600684. DOI: 10.3390/curroncol29100575.


Comparative Oncology: Management of Hepatic Neoplasia in Humans and Dogs.

Gibson E, Goldman R, Culp W Vet Sci. 2022; 9(9).

PMID: 36136704 PMC: 9505178. DOI: 10.3390/vetsci9090489.


Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.

Zhou Q, Wang X, Li R, Wang C, Wang J, Xie X J Gastroenterol. 2022; 57(9):684-694.

PMID: 35816221 PMC: 9392709. DOI: 10.1007/s00535-022-01895-3.


References
1.
Lau W, Lai E, Leung T, Yu S . Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg. 2007; 247(1):43-8. DOI: 10.1097/SLA.0b013e3181571047. View

2.
Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

3.
Arii S, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M . Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg. 1998; 5(1):86-92. DOI: 10.1007/pl00009956. View

4.
Wong J, Wong G, Tsoi K, Wong V, Cheung S, Chong C . Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011; 33(10):1104-12. DOI: 10.1111/j.1365-2036.2011.04634.x. View

5.
Chua T, Morris D . Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol. 2011; 21(2):95-101. DOI: 10.1016/j.suronc.2011.01.005. View